Can a higher dose of an existing drug preserve lung function in Alpha-1 patients?
NCT ID NCT07326592
First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests whether higher doses of the drug Respreeza/Zemaira, given as weekly IV infusions over 3 years, can slow the loss of lung density in adults with emphysema caused by Alpha-1 antitrypsin deficiency. About 270 participants aged 18-65 with a confirmed genetic form of the disease will be randomly assigned to one of three dose levels. The goal is to find the best dose to preserve lung health and slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.